Not provided
Not provided
Not provided
Not provided
Not provided
The study was withdrawn due to change in project strategy (new intended use)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This pivotal multicenter study has been launched to collect spectral Raman data paired with validated glucose reference values in diabetic patients.
Participants will be enrolled at six different sites in four different countries. All participants will undergo identical procedures, which include four steps: Baseline visit (1 day), calibration period (25 days), validation period (23 days) and a close-out visit (1 day) with a total duration of 50 days.
The calibration period consists of 23 home-based days and two in-clinic days. At the two in-clinic days, measurement sessions are performed every 30 minutes. A measurement session consists of two reference measurements (Contour Next One) and three measurements on the Investigational Medical Device. The glucose level of the participants is manipulated by administration of a glucose rich drink. At home-based days, the subject must perform four measurement sessions a day. During the validation period, participants perform up to four home-based measurement sessions a day.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| RSP-20 | Experimental | Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 48 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prototype 0.5 | Device | Investigational Medical Device collecting spectral Raman data non-invasively from tissue |
|
| Measure | Description | Time Frame |
|---|---|---|
| Measurement accuracy | Accuracy of measurements performed on the IMD will be evaluated by data from subjects. Data will be analyzed by Mean Absolute Relative Difference (MARD). | 6 months |
| Safety evaluation: paucity of adverse events | Safety of the IMD will be evaluated in a descriptive manner by the paucity of adverse events reported during the clinical study | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Device deficiencies | Description of device deficiencies will be listed. Deficiencies will be reported during the clinical study. | Up to 6 months |
| Device usability | The use of the device will be evaluated by means of questionnaires. The subjects are asked if they encountered any problems during measurements, and if so, to elaborate the problems encountered. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kirsten Nørgaard, MD | Steno Diabetes Center Copenhagen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Steno Diabetes Center Copenhagen (SDCC) | Gentofte Municipality | 2820 | Denmark | |||
| Steno Diabetes Center Odense (SDCO) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 months |
| Odense C |
| 5000 |
| Denmark |
| Institut für Diabetes-Technologie Forschungs- und Entwicklungs-gesellschaft mbH an der Universität Ulm (IDT) | Ulm | 89081 | Germany |
| Sahlgrenske University Hospital (SUH) | Gothenburg | 413 45 | Sweden |
| Department of Medicine, Uddevalla Hospital (UVH) | Uddevalla | 451 53 | Sweden |
| University Hospitals Birmingham (UHB) | Birmingham | United Kingdom |